PTC Therapeutics is transitioning from a legacy rare disease business to a growth-focused model. Read why PTCT stock is a Buy ...
Shares of PTC Therapeutics (PTCT) added ~19% on Friday to reach the highest level since January after the rare disease ...
PTC Therapeutics (NASDAQ:PTCT) reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria, or ...
PTC (NASDAQ: PTC) today announced the U.S. Army has designated the Windchill® product lifecycle management (PLM) solution as ...
Q1 2026 earnings call recap: record revenue, raised 2026 guidance, Sephience launch momentum, Japan entry & pipeline ...
Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.
What Happened? Shares of product design software company PTC (NASDAQ:PTC) jumped 8.9% in the afternoon session after the ...
PTC Therapeutics draws market attention after a stronger quarterly update highlights rare disease focus and healthcare sector ...
Phase 2 data from PTC Therapeutics showed that the Novartis-partnered Huntington’s disease asset slowed progression by more ...
May 6 - PTC Inc on Wednesday raised its full-year revenue forecast, citing continued demand from manufacturers using its software to digitize their design and production processes. Shares of the ...